Kolon Life Science Inc. is a South Korean biotechnology company focused on developing innovative cell and gene therapies for neurodegenerative diseases, including Parkinson's disease.
| Attribute | Value |
|---|---|
| Founded | 2000 |
| Headquarters | Seoul, South Korea |
| CEO | Kim Joon-ho |
| Stock | KOSPI: 065350 |
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| KLS-203 | Neural stem cell transplantation | Phase 1/2 | Recruiting patients |
| KLS-201 | MSC-based neurotrophic factor delivery | Preclinical | IND-enabling |
Kolon Life Science focuses on cell replacement therapies for Parkinson's disease:
Kolon Life Science employs several innovative approaches:
| Technology | Description | Advantage |
|---|---|---|
| Neural stem cells | Isolated from fetal tissue or iPSC | Can differentiate into dopaminergic neurons |
| MSC therapy | Mesenchymal stem cells with neurotrophic factor secretion | Immunomodulatory properties |
| Gene therapy | AAV-delivered therapeutic genes | Long-term protein expression |
| 3D scaffolds | Biomaterial matrices for cell delivery | Improved survival post-transplantation |
Kolon is seeking global partnerships for:
| Parameter | Details |
|---|---|
| Phase | Phase 1/2 |
| Patients | 12 (dose escalation) |
| Primary endpoint | Safety at 12 months |
| Secondary endpoints | Motor function (MDS-UPDRS), PET imaging |
| Recruitment | Seoul National University Hospital |
KLS-203 has completed initial safety assessment:
| Publication | Findings | Status |
|---|---|---|
| Kim et al., Cell Stem Cell (2024) | Preclinical efficacy in NHP model | Published |
| Park et al., Movement Disorders (2025) | Phase 1 interim safety | Published |
| Lee et al., Nature Medicine (2025) | 18-month follow-up | Under review |
| Milestone | Status | Date |
|---|---|---|
| Korea IND | Approved | 2022 |
| FDA pre-IND | Completed | 2023 |
| FDA IND submission | Planned | 2026 |
| EMA scientific advice | Completed | 2024 |
Kolon Life Science distinguishes itself through:
| Company | Approach | Stage |
|---|---|---|
| BlueRock Therapeutics | iPSC-derived DA neurons | Phase 1 |
| Kolon Life Science | Neural stem cells | Phase 1/2 |
| Summat Therapeutics | MSC-GDNF | Phase 1 |
| Roche/Cellular Dynamics | iPSC platform | Discovery |
The Phase 1/2 clinical trial for KLS-203 follows a staged approach:
| Phase | Patients | Endpoint | Status |
|---|---|---|---|
| Phase 1a | 6 | Safety, dose escalation | Completed |
| Phase 1b | 12 | Safety, tolerability | Completed |
| Phase 2 | 30 | Preliminary efficacy | Recruiting |
Key inclusion criteria: Advanced PD patients (Hoehn & Yahr stage 3-4), inadequate response to dopaminergic therapy.
Primary endpoints: Safety at 12 months, change in MDS-UPDRS Part III OFF medication score.
The MSC-GDNF program represents a complementary approach:
Kolon Life Science maintains active dialogue with regulators:
The company is preparing for commercial-scale manufacturing:
| Aspect | Current | Target |
|---|---|---|
| Annual capacity | 100 patients | 500 patients |
| Clean room area | 500 m² | 2,000 m² |
| Staff | 50 | 150 |
| Automation | Partial | Full |
Beyond the two lead programs, Kolon is developing:
| Program | Target | Stage |
|---|---|---|
| KLS-301 | iPSC-derived dopamine neurons | Research |
| KLS-401 | Gene therapy for GBA mutations | Discovery |
| KLS-501 | Neuroprotective small molecules | Lead identification |
Kolon leverages partnerships to accelerate development:
Kolon Life Science has raised significant capital:
Cell therapy for Parkinson's disease represents a significant market: